Successful combination therapy with ustekinumab and intensive granulocyte and monocyte adsorptive apheresis in highly refractory pediatric ulcerative colitis: pathophysiological rationale and clinical outcome.

Remicade (infliximab) - J&J

Humira (adalimumab) - AbbVie

Stelara (ustekinumab) - J&J

Entyvio (vedolizumab) - Takeda

http://www.ncbi.nlm.nih.gov/pubmed/42784247

Gaku Yamanaka; Masakatsu Fukuzawa; Miki Eto Tanaka; Naoko Saito; Norito Tsutsumi; Shigeo Nishimata; Shun Watanabe; Tadashi Ichimiya; Yasuyo Kashiwagi; Yu Kamei

Sep 25, 2026